Ceribell, Inc.
CBLLNasdaq
$18.72
↓ -2.2%Jul 17 close · end-of-day
Price
1Y↑ +18.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$705.1M
Enterprise Value
$563.9M
P/E
—
P/S
7.4
P/B
5.0
EV/EBITDA
—
PEG
—
FCF Yield
-7.0%
Dividend Yield
—
Revenue (TTM)
$95.1M
Net Income (TTM)
-$60.4M
Free Cash Flow (TTM)
-$49.4M
Gross Margin
87.7%
Operating Margin
-68.3%
Net Margin
-63.5%
ROE
-42.9%
ROIC
—
Debt / Equity
—
Net Cash
$141.2M
Return 1Y
+19.9%
Company profile
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We were incorporated under the laws of the State of Delaware on August 29, 2014, under the name “Brain Stethoscope, Inc.” and changed our name to CeriBell, Inc. on August 11, 2015. Our principal executive offices are located at 360 N. Pastoria Avenue, Sunnyvale, California.
- CEO
- Xingjuan (Jane) Chao
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Headquarters
- California
- Website
- www.ceribell.com/
Management & directors
- Chao XingjuanPresident and CEO
- Foehr DavidSenior VP, Finance and PAO
- Blumberg ScottChief Financial Officer
- Manni Joseph S.Chief Revenue Officer
- Woo RaymondChief Technology Officer
Roles derived from SEC Form 4 filings.
Earnings
CBLL Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$26.5M↑ +29.3%
Diluted EPS-$0.52↑ +44.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $45.2M | $65.4M | $89.1M |
| Gross profit | $38.2M | $56.8M | $78.3M |
| Operating income | -$30.0M | -$39.7M | -$58.4M |
| Net income | -$29.5M | -$40.5M | -$53.4M |
| Diluted EPS | -$5.56 | -$3.39 | -$1.46 |
| Operating cash flow | -$29.2M | -$35.0M | -$40.8M |
| Free cash flow | -$30.1M | -$36.4M | -$41.6M |
| Gross margin | 84.4% | 86.7% | 87.9% |
| Operating margin | -66.4% | -60.7% | -65.6% |
| Net margin | -65.1% | -61.8% | -60.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.3M | $17.2M | $18.5M | $20.5M | $21.2M | $22.6M | $24.8M | $26.5M |
| Gross profit | $13.2M | $15.0M | $16.2M | $18.0M | $18.7M | $19.9M | $21.6M | $23.1M |
| Operating income | -$8.4M | -$9.9M | -$12.9M | -$14.2M | -$15.0M | -$14.6M | -$14.6M | -$20.7M |
| Net income | -$8.9M | -$10.4M | -$12.6M | -$12.8M | -$13.6M | -$13.5M | -$13.5M | -$19.7M |
| Diluted EPS | -$1.61 | -$1.85 | $1.63 | -$0.36 | -$0.38 | -$0.37 | -$0.35 | -$0.52 |
| Operating cash flow | -$7.0M | -$8.5M | -$10.0M | -$11.4M | -$7.5M | -$11.1M | -$10.8M | -$19.3M |
| Free cash flow | -$7.3M | -$9.1M | -$10.3M | -$11.6M | -$7.6M | -$11.5M | -$11.0M | -$19.4M |
| Gross margin | 85.9% | 87.3% | 87.6% | 87.9% | 88.1% | 88.3% | 87.3% | 87.3% |
| Operating margin | -55.1% | -57.8% | -69.5% | -69.3% | -70.5% | -64.8% | -58.9% | -78.3% |
| Net margin | -58.4% | -60.6% | -67.9% | -62.4% | -64.4% | -59.6% | -54.6% | -74.5% |
Company news
Jul 20, 2026
Jun 27, 2026
May 20, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-07 | Chao Xingjuan· President and CEO | Sale | 23,554 | $19.90 | $468,724.60 | filing |
| 2026-07-07 | Chao Xingjuan· President and CEO | Sale | 14,000 | $19.90 | $278,600.00 | filing |
| 2026-07-07 | Chao Xingjuan· President and CEO | Option exercise | 23,554 | $4.70 | $110,703.80 | filing |
| 2026-07-07 | Chao Xingjuan· President and CEO | Sale | 1,446 | $19.90 | $28,775.40 | filing |
| 2026-07-07 | Chao Xingjuan· President and CEO | Option exercise | 1,446 | $4.70 | $6,796.20 | filing |
| 2026-06-30 | BURKE WILLIAM W | Sale | 2,207 | $19.84 | $43,786.88 | filing |
| 2026-06-26 | TPG GP A, LLC | Sale | 202,368 | $20.12 | $4.1M | filing |
| 2026-06-11 | Taylor Joseph Michael | Sale | 5,500 | $18.41 | $101,255.00 | filing |
| 2026-06-08 | Chao Xingjuan· President and CEO | Sale | 23,554 | $18.33 | $431,744.82 | filing |
| 2026-06-08 | Chao Xingjuan· President and CEO | Sale | 14,000 | $18.33 | $256,620.00 | filing |
| 2026-06-08 | Chao Xingjuan· President and CEO | Option exercise | 23,554 | $4.70 | $110,703.80 | filing |
| 2026-06-08 | Chao Xingjuan· President and CEO | Sale | 1,446 | $18.33 | $26,505.18 | filing |
| 2026-06-08 | Chao Xingjuan· President and CEO | Option exercise | 1,446 | $4.70 | $6,796.20 | filing |
| 2026-06-02 | Rogers Erica J. | Award | 7,838 | $0.00 | $0.00 | filing |
| 2026-06-02 | Tammenoms Bakker Juliet | Award | 7,838 | $0.00 | $0.00 | filing |
| 2026-06-02 | Parvizi Josef | Award | 7,838 | $0.00 | $0.00 | filing |
| 2026-06-02 | BURKE WILLIAM W | Award | 7,838 | $0.00 | $0.00 | filing |
| 2026-06-02 | Taylor Joseph Michael | Award | 7,838 | $0.00 | $0.00 | filing |
| 2026-06-02 | ROBERTSON REBECCA B | Award | 7,838 | $0.00 | $0.00 | filing |
| 2026-05-22 | Foehr David· Senior VP, Finance and PAO | Sale | 862 | $18.80 | $16,205.60 | filing |
| 2026-05-21 | Chao Xingjuan· President and CEO | Sale | 6,030 | $18.00 | $108,540.00 | filing |
| 2026-05-21 | Woo Raymond· Chief Technology Officer | Sale | 1,966 | $18.00 | $35,388.00 | filing |
| 2026-05-21 | Blumberg Scott· Chief Financial Officer | Sale | 1,387 | $18.00 | $24,966.00 | filing |
| 2026-05-21 | Manni Joseph S.· Chief Revenue Officer | Sale | 1,378 | $18.00 | $24,804.00 | filing |
| 2026-05-21 | Foehr David· Senior VP, Finance and PAO | Sale | 987 | $18.00 | $17,766.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.